Hong Kong Real Estate Stock News

Blue Moon Group Holdings (SEHK:6993) issued new earnings guidance, telling investors it expects at least a 50% reduction in its 2025 loss compared with the HK$749.3 million loss recorded for 2024. See our latest analysis for Blue Moon Group Holdings. That guidance landed alongside a 1 day share price return of 4.56% and a year to date share price return of 8.76% at HK$2.98. However, the 1 year total shareholder return of 13.58% and 5 year total shareholder return of 77.98% show that longer...

Why Sihuan Pharmaceutical’s latest filler approval matters for investors Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that six additional specifications of its polylactic acid facial filler received approval from China’s National Medical Products Administration, expanding its medical aesthetics product range to allow more tailored anti aging treatments. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The latest PLLA filler approvals come after a strong...

Why MicroPort Scientific’s latest guidance matters MicroPort Scientific (SEHK:853) has told investors it expects a turnaround to profitability in 2025, guiding to net profit of at least US$20 million after reporting an audited 2024 net loss of about US$268 million. See our latest analysis for MicroPort Scientific. The guidance appears to have arrived alongside a shift in sentiment, with a 1 month share price return of 18.17% and year to date share price return of 19.81%. The 1 year total...

Kuaishou Technology recently completed multi-currency fixed-rate senior unsecured bond offerings, raising about US$1.49 billion and CNY 3.50 billion with maturities extending to 2036, while reporting December 2025 monthly revenue above US$20 million. At the same time, its AI video-generation tool Kling surpassed 12 million monthly active users, underscoring how artificial intelligence is becoming a core pillar of Kuaishou’s business model and product appeal. We’ll now examine how the...

Why this dual drug news matters for CSPC Pharmaceutical Group (SEHK:1093) CSPC Pharmaceutical Group (SEHK:1093) has just reported two pipeline milestones, US and China trial approvals for its aldosterone synthase inhibitor SYH2072 in hypertension and a fresh China filing for a fixed dose diabetes combination. For investors, these updates highlight activity in both early clinical development and late stage commercial readiness. This helps frame how the stock might reflect CSPC's current...

Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data. This milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China. We’ll now examine how gumokimab’s sNDA acceptance, supported by...

Why Pop Mart’s new buyback is back in focus Pop Mart International Group (SEHK:9992) has kicked off a sizeable share repurchase program, targeting up to 10% of its issued capital after shareholder approval, and the move has quickly sharpened market attention. See our latest analysis for Pop Mart International Group. The buyback news landed on a market already seeing a sharp swing in sentiment, with a 7 day share price return of 22.96% and a 1 year total shareholder return of 140.99% following...

Key Insights Significant insider control over Skyworth Group implies vested interests in company growth The largest...

Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...

With its stock down 15% over the past three months, it is easy to disregard TUHU Car (HKG:9690). But if you pay close...

Most readers would already be aware that EPS Creative Health Technology Group's (HKG:3860) stock increased...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Ching Lee Holdings Limited's ( HKG:3728 ) price-to-earnings (or "P/E") ratio of 7.5x might make it look like a buy...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

While Huili Resources (Group) Limited ( HKG:1303 ) shareholders are probably generally happy, the stock hasn't had...

Viva Biotech Holdings ( HKG:1873 ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...

JTF International Holdings Limited ( HKG:9689 ) shareholders have had their patience rewarded with a 54% share price...

Despite an already strong run, Sheung Yue Group Holdings Limited ( HKG:1633 ) shares have been powering on, with a gain...

Key Insights The considerable ownership by private companies in China National Building Material indicates that they...

Despite an already strong run, Vision Values Holdings Limited ( HKG:862 ) shares have been powering on, with a gain of...

Key Insights The considerable ownership by individual investors in Shanghai Fudan Microelectronics Group indicates that...

Why WH Group Is On Investors’ Radar Today WH Group (SEHK:288) has drawn attention after a period where its share price performance and fundamentals tell a mixed story, inviting investors to reassess how its valuation lines up with recent business results. See our latest analysis for WH Group. While WH Group’s share price is close to HK$8.79 after a modest 0.11% 1 day share price return, the 18.78% 90 day share price return and 63.87% 1 year total shareholder return suggest momentum has...

China Unicom (Hong Kong) Limited recently appointed Dong Xin as both Chairman and Chief Executive Officer, effective January 14, 2026, consolidating its top leadership roles under a single executive. By bringing in the existing head of China United Network Communications Group and China United Network Communications Corporation, the company is tightening alignment with its state-owned parent structure, which could influence future corporate priorities and governance. We will now examine...